title: Evaluation of the long-term cost-effectiveness of liraglutide vs lixisenatide for treatment of type 2 diabetes mellitus in the UK setting.
abstract: To compare the cost-effectiveness of 2 glucagon-like peptide-1 (GLP-1) receptor agonists, liraglutide 1.8 mg and lixisenatide 20 µg, in the UK setting based on the LIRA-LIXI trial (NCT01973231).
  
  
  
  Projections of costs (in 2015 pounds sterling [£]) and clinical outcomes were made over patient lifetimes using the IMS CORE Diabetes Model (IMS Health, Basel, Switzerland). The baseline cohort and treatment effects applied after initiation of GLP-1 receptor agonists were taken from the LIRA-LIXI trial. Future costs and clinical benefits were discounted at 3.5% annually.
  
  
  
  Liraglutide 1.8 mg was associated with improved discounted quality-adjusted life expectancy (8.87 vs 8.76 quality-adjusted life years [QALYs]) vs lixisenatide 20 µg. A greater reduction in glycated haemoglobin with liraglutide 1.8 mg led to fewer diabetes-related complications and delayed their time of onset. Liraglutide 1.8 mg was associated with increased total costs (£37 153 vs £36 174), driven by higher acquisition costs, but this was partially offset by savings from diabetes-related complications avoided (£26 969 vs £27 912). Liraglutide 1.8 mg was associated with an incremental cost-effectiveness ratio of £8901 per QALY gained vs lixisenatide 20 µg.
  
  
  
  Long-term projections suggest that treatment of patients with type 2 diabetes with liraglutide 1.8 mg is likely to be considered highly cost-effective compared with lixisenatide 20 µg treatment in the UK setting.
authors.affiliation: Ossian Health Economics and Communications, Basel, Switzerland.
authors.forename: Barnaby
authors.identifier: 0000-0001-5420-279X
authors.initials: B
authors.lastname: Hunt
authors.affiliation: Novo Nordisk Ltd, Gatwick, UK.
authors.forename: Gabriela
authors.initials: G
authors.lastname: Vega-Hernandez
authors.affiliation: Ossian Health Economics and Communications, Basel, Switzerland.
authors.forename: William J
authors.initials: WJ
authors.lastname: Valentine
authors.affiliation: Novo Nordisk A/S, Søborg, Denmark.
authors.forename: Nana
authors.initials: N
authors.lastname: Kragh
mesh_terms: D000328:Adult; D015331:Cohort Studies; D003362:Cost-Benefit Analysis; D048909:Diabetes Complications / Q000191:economics / Q000209:etiology; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy* / Q000191:economics; D005260:Female; D006442:Glycated Hemoglobin / Q000187:drug effects; D006801:Humans; D007004:Hypoglycemic Agents / Q000191:economics*; D000069450:Liraglutide / Q000191:economics*; D008297:Male; D008875:Middle Aged; D010455:Peptides / Q000191:economics*; D019057:Quality-Adjusted Life Years; D006113:United Kingdom; D000067758:Glucagon-Like Peptide-2 Receptor
chemical_list: D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D000069450:Liraglutide; D010455:Peptides; C517652:hemoglobin A1c protein, human; C479460:lixisenatide; D000067758:Glucagon-Like Peptide-2 Receptor
keywords: GLP-1 analogue; antidiabetic drug; cost-effectiveness; incretin therapy; liraglutide; type 2 diabetes